Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?

insidermonkey.com · 2026-10-16

Pfizer Inc. (NYSE:PFE) trades at a considerable discount to AbbVie Inc. (NYSE:ABBV), despite both companies reporting growth in important parts of their pharmaceutical portfolios.

TickrTrends take: Pfizer trades at a valuation that TickrTrends currently assesses as overvalued relative to fundamentals, which makes direct cost comparisons with competitors like AbbVie a relevant analytical exercise for value-conscious investors. The healthcare sector contains significant variation in how individual companies are priced relative to their earnings and assets, so a stock trading at a lower absolute price does not necessarily indicate better valuation. Investors focused on valuation metrics should monitor whether Pfizer's current premium valuation persists or compresses as the company's business performance evolves.

Read the full story at insidermonkey.com →